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Clinical PerspectiveWhat Is New?Familial hypercholesterolemia is characterized by lifelong elevation of circulating low‐density lipoproteins and is associated with high cardiovascular mortality and morbidity; however, because of the variability in its presentation and lack of awareness, the condition is often underdiagnosed.Within our integrated health system, we evaluated novel ways of identifying and examining the sequelae of familial hypercholesterolemia in a population‐based manner.This was done by using an electronic health record--based algorithm for detection and risk stratification of familial hypercholesterolemia and its associated comorbidities and cardiovascular outcomes and by using the total cost of care to examine the higher cost per year associated with the various categories of the familial hypercholesterolemia phenotype.What Are the Clinical Implications?This methodology can allow health systems to study the drivers of worse clinical outcomes and higher costs of care to identify areas of opportunity to target limited resources.

Introduction {#jah34215-sec-0008}
============

The precision medicine model proposes customization of health care to individual patients, the success of which is largely dependent on early and accurate diagnosis. Familial hypercholesterolemia (FH)---a genetic disorder characterized by elevated low‐density lipoprotein cholesterol (LDL‐C) levels and early cardiovascular disease, is 1 of the 3 Centers for Disease Control and Prevention (CDC) designated Tier 1 public health genomic conditions, based on available evidence‐based guidelines.[1](#jah34215-bib-0001){ref-type="ref"} The major clinical manifestation of FH, premature atherosclerosis, is thought to result from the prolonged exposure of the vasculature to high levels of LDL‐C. Clinical cardiovascular heart disease occurs at a higher frequency and at an earlier age in patients with FH than in patients without FH or patients with polygenetic causes of elevated LDL‐C.[2](#jah34215-bib-0002){ref-type="ref"} Traditional estimates of FH in the general population vary significantly, from 1:500 to 1:137,[3](#jah34215-bib-0003){ref-type="ref"} with the added challenge of lack of specific *International Classification of Diseases* (*ICD*) coding until recently. Despite advances in our understanding of the pathophysiology of FH, significant numbers remain undiagnosed and undertreated in relation to LDL‐C targets.[4](#jah34215-bib-0004){ref-type="ref"} While the cost effectiveness of universal screening, early identification, and treatment is still evolving,[5](#jah34215-bib-0005){ref-type="ref"} availability of electronic health records (EHRs) and validated clinical criteria may offer a rapid and efficient approach to population‐based screening to identify high‐risk individuals for targeted interventions. Additionally, evaluation of interventions in FH is complicated by the paucity of relevant economic data.[6](#jah34215-bib-0006){ref-type="ref"} The goal of this study is to use EHR‐based algorithms to implement a population‐based screening approach to identify the hidden burden of FH and study the trends of major adverse cardiovascular events (MACE), mortality and cost of care associated with this diagnosis.

Methods {#jah34215-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Data Extraction {#jah34215-sec-0010}
---------------

We queried our EHR database of over 1.5 million Geisinger Health System (GHS) patients (January 2000 to August 2016) with *ICD, Ninth Revision* (*ICD‐9*) codes for hyperlipidemia (272.0, 272.1, 272.2, 272.3, 272.4). This project was approved as an expedited study on the basis of use of deidentified data by the Institutional Review Board at Geisinger Medical Center. We excluded patients aged \<18 years or ≥85 years, leaving an eligible study population of 1.18 million patients. An internally validated algorithm (see below) developed at Geisinger using modified Dutch Lipid Clinic Network Criteria (DLCN) (Table [S1](#jah34215-sup-0001){ref-type="supplementary-material"}) was applied to these patients to categorize them into definite, probable, possible, and unlikely FH categories.[7](#jah34215-bib-0007){ref-type="ref"} The DLCN criteria were modified (Tables [S2 and S3](#jah34215-sup-0001){ref-type="supplementary-material"}) to suit the EHR‐derived data set. The first 3 of these discrete groups was defined to represent the hidden burden of FH in our population and were analyzed together as the "FH cohort."

The EHR‐based algorithm based on the modified DLCN criteria for FH using a structured data set was validated internally by chart reviewing 250 randomly chosen case and control patients (definite, 2; probable, 13; possible, 111; unlikely, 124). A total of 125 of 126 patients were found to be accurately assigned to the positive group by the algorithm, for a positive predictive value of 99.21%. A total of 118 of 124 were found to be true‐negative patients (unlikely FH), for a negative predictive value of 95.16% (for details of diagnostic accuracy see Tables [S4 and S5](#jah34215-sup-0001){ref-type="supplementary-material"}). Six patients moved from the unlikely category to possible, for a sensitivity score of 95.42%. One patient went from possible to unlikely, for a specificity score of 99.16% (Table [S6](#jah34215-sup-0001){ref-type="supplementary-material"}). Ten patients had errors found but stayed unlikely, and 1 patient remained in the definite category. Six of the 10 algorithm definitions were found to have 100% accuracy after chart reviews. Our EHR‐based algorithm for identifying relevant family history in first‐degree relatives performed poorly. Ten additional patients were found to have a family history of heart disease during the chart review of clinic notes, and 2 patients were deemed to have a family history of hyperlipidemia.

Outcomes {#jah34215-sec-0011}
--------

Primary outcomes of interest were MACE, mortality, and cost of care.

Mortality {#jah34215-sec-0012}
---------

Mortality was defined as all‐cause mortality identified within the EHR. Our database interfaces with the Social Security Death Index on a biweekly basis to reflect updated information on vital status.

Major Adverse Cardiovascular Events {#jah34215-sec-0013}
-----------------------------------

MACE was defined as a categorical variable denoting occurrence of the first instance of any of the following: all‐cause death, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass. Each of these clinical events were identified by using *ICD‐9* codes (Table [S7](#jah34215-sup-0001){ref-type="supplementary-material"}) in patients' EHR to obtain information relevant to MACE. Validation of the EHR‐derived MACE and clinical variables was done by manual chart review in 100 randomly chosen subjects and showed good diagnostic accuracy (95% myocardial infarction, 95% heart failure, 100% ischemic stroke, 100% percutaneous coronary intervention, 100% bypass grafting, and 100% *ICD*).

Cost of Care {#jah34215-sec-0014}
------------

To identify the hidden economic burden of FH on healthcare system, we sought to determine differences in medical care expenditures between FH and non‐FH hyperlipidemia cohorts on the basis of revenue data from medical care service use within our health system. Because of stepwise integration of several satellite sites within the system, financial data were not available for early years and some patients. We dealt with this by analyzing the clinical characteristics of patients with missing data to those with available data and using complete case analysis only. Inflation adjusted financial data for each year were calculated in terms of the 2015 data, according to the latest consumer price index data.[8](#jah34215-bib-0008){ref-type="ref"} We then compared adjusted median revenue between the 2 groups for the years 2005 through 2015. Because the revenue received by the healthcare system may vary depending on the payer mix, to calculate the absolute magnitude of difference in expenditure between the 2 groups we used a variable "Med Net Revenue," which adjusts all payer revenues to Medicare rates for GHS. These data were available only for the years 2014 and 2015.

Data Analyses {#jah34215-sec-0015}
-------------

Statistical Analysis System (SAS) Version 9.4 (SAS Institute Inc., Cary, NC) was used for statistical analyses. Descriptive variables were expressed as mean with standard deviation in cases of normal distribution, and median with interquartile range (IQR) in case of nonnormal distribution. Normality was assessed by the Kolmogorov--Smirnoff test. Categorical variables are expressed as counts with percentages. Comparisons between continuous variables were conducted with nonparametric Mann--Whitney test for mean ranks for those variables with nonnormal distribution, whereas the chi‐square test was performed to test the independence of categorical variables. To account for biases attributable to the observed confounders from baseline characteristics, the stabilized inverse probability of treatment weights was implemented by weighting the responses on the basis of their propensity scores in the regression model. The propensity scores were estimated on the basis of observed confounders that were significantly different between FH and non‐FH cohorts including age, sex, smoking history, comorbid conditions, and the lost to follow‐up indicator. Lost to follow‐up was defined as no visit in EHR 2 years before the end of the study. A priori associated variables/confounders were included in the logistic regression, after adjusting for age, sex, smoking status, diabetes mellitus, hypertension, and LDL‐C (maximum) values to evaluate if EHR FH significantly predicted outcomes.[9](#jah34215-bib-0009){ref-type="ref"} Odds ratios with corresponding 95% CIs were presented. By including the total follow‐up time (defined as the years between first and last encounter over 2005--2015) as the offset variable to normalize the total adjusted revenue to a per‐year basis, a negative binomial regression model using inverse probability of treatment weights was performed to evaluate the impact of FH on the total revenue after adjusting for a priori associated variables/confounders. Incidence rate ratios with corresponding 95% CIs were presented. A *P* value of \<0.05 was considered significant.

Results {#jah34215-sec-0016}
=======

In our 1.18 million EHR‐eligible cohort, 237 903 patients had hyperlipidemia (49.5% female, 96.6% white). Median age of the entire cohort was 63 years (IQR, 20 years), with an overall available median EHR follow‐up of 10 years (IQR, 11 years). FH phenotype was identified using the EHR‐based algorithm in 32 613 individuals, which was 2.76% of the entire EHR cohort (definite, 0.03%; probable, 0.16%; possible, 2.55%) and constituted 13.7% of patients with hyperlipidemia (Figure [1](#jah34215-fig-0001){ref-type="fig"}).

![FH categories within hyperlipidemia cohort of 237 903 individuals. FH indicates familial hypercholesterolemia.](JAH3-8-e011822-g001){#jah34215-fig-0001}

In univariate analysis, the FH cohort was noted to have a higher percentage of females (56.52% versus 48.51%; *P*\<0.0001) and history of smoking (54.11% versus 50.73%; *P*\<0.0001). Baseline demographic characteristics as well as use of medications and diagnostics tests in 2 groups are shown in Table [1](#jah34215-tbl-0001){ref-type="table"}. Deceased patients in the FH cohort were younger at the time of death compared with those in the non‐FH cohort (median, 70 years versus 75 years; *P*\<0.0001). Cumulatively, a MACE event was observed at a younger age in the FH cohort (54 years versus 67 years; *P*\<0.0001). Patients in the FH cohort experienced higher rate of specific MACE events, including myocardial infarction (14.77% versus 8.33%; *P*\<0.0001) and heart failure (11.82% versus 10.50%; *P*\<0.0001) (Table [2](#jah34215-tbl-0002){ref-type="table"}). Furthermore, total cholesterol, triglycerides, LDL‐C, and high‐density lipoprotein cholesterol levels were all higher in the FH cohort (Table [1](#jah34215-tbl-0001){ref-type="table"}). The FH cohort had a significantly higher median value of maximum LDL‐C levels (highest LDL‐C documented in EHR per patient) compared with that in non‐FH cohort (202 mg/dL versus 137 mg/dL; *P*\<0.0001). Analysis of medication data revealed higher use of statins (79.10% versus 57.82%; *P*\<0.0001), high‐potency statins (42.15% versus 19.49%; *P*\<0.0001), and proprotein convertase subtilisin/kexin type 9 inhibitors (0.18% versus 0.02%; *P*\<0.0001) in FH cohort compared with their non‐FH counterparts (Table [1](#jah34215-tbl-0001){ref-type="table"}). Overall, there were a total of 11.3% lost to follow‐up for MACE, and 12.5% lost to follow‐up for mortality. In the logistic regression model, by weighting the responses on the basis of their propensity scores (inverse probability of treatment weights), EHR FH correlated with MACE (incidence rate ratio, 4.02; 95% CI, 3.88--4.16; *P*\<0.0001) and mortality (incidence rate ratio, 1.20; 95% CI, 1.15--1.26; *P*\<0.0001) after adjusting for descriptive characteristics that differed between cohorts such as age, sex, smoking status, diabetes mellitus, hypertension, and maximum LDL (Figure [2](#jah34215-fig-0002){ref-type="fig"}).

###### 

Univariate Comparison of Baseline Characteristics Between FH and Non‐FH Hyperlipidemia Cohort

                                                                FH Cohort   Non‐FH Cohort   *P* Value           
  ------------------------------------------------------------- ----------- --------------- ----------- ------- -----------
  Total                                                         32 613      13.71           205 290     86.29   
  Sex (male)                                                    14 179      43.48           105 696     51.49   \<0.0001
  Race (white, inclusive of Hispanic ethnicity)                 31 860      97.69           198 135     96.51   \<0.0001
  Smoking history (yes)                                         17 647      54.11           104 132     50.73   \<0.0001
  Medications                                                                                                   
  Statins                                                       25 796      79.10           118 688     57.82   \<0.0001
  High‐potency statins[a](#jah34215-note-0003){ref-type="fn"}   13 747      42.15           40 008      19.49   \<0.0001
  PCSK‐9 inhibitors                                             59          0.18            51          0.02    \<0.0001
  β‐blockers                                                    13 288      40.74           68 062      33.15   \<0.0001
  Calcium channel blockers                                      7490        22.97           44 186      21.52   \<0.0001
  ACE inhibitors                                                14 034      43.03           79 250      38.60   \<0.0001
  Loop diuretics                                                6349        19.47           35 288      17.19   \<0.0001
  Antiplatelets                                                 5837        17.90           22 431      10.93   \<0.0001
  Anticoagulants                                                4712        14.45           28 585      13.92   0.01
  Diagnostic tests                                                                                              
  ECG                                                           23 740      72.79           132 775     64.69   \<0.0001
  Echocardiogram                                                15 439      47.34           77 316      37.66   \<0.0001
                                                                Median      IQR             Median      IQR     *P* Value
  Age                                                           61          17              63          19      \<0.0001
  Lipid profiles                                                                                                
  Total cholesterol                                                                                             
  Maximum[b](#jah34215-note-0004){ref-type="fn"}                264         40              194         57      \<0.0001
  Average[c](#jah34215-note-0005){ref-type="fn"}                200         42              161         45      \<0.0001
  Delta[d](#jah34215-note-0006){ref-type="fn"}                  131         68              58          70      \<0.0001
  LDL cholesterol                                                                                               
  Maximum[b](#jah34215-note-0004){ref-type="fn"}                202         27              137         49      \<0.0001
  Average[c](#jah34215-note-0005){ref-type="fn"}                148         35              110         38      \<0.0001
  Delta[d](#jah34215-note-0006){ref-type="fn"}                  111         61              42          59      \<0.0001
  HDL cholesterol                                                                                               
  Maximum[b](#jah34215-note-0004){ref-type="fn"}                57          21              54          22      \<0.0001
  Average[c](#jah34215-note-0005){ref-type="fn"}                49          17              48          19      \<0.0001
  Delta[d](#jah34215-note-0006){ref-type="fn"}                  18          15              12          16      \<0.0001
  Triglycerides                                                                                                 
  Maximum[b](#jah34215-note-0004){ref-type="fn"}                237         163             181         144     \<0.0001
  Average[c](#jah34215-note-0005){ref-type="fn"}                171         105             143         100     \<0.0001
  Delta[d](#jah34215-note-0006){ref-type="fn"}                  133         142             75          122     \<0.0001

ACE indicates angiotensin‐converting enzyme; FH, familial hypercholesterolemia; HDL, high‐density lipoprotein; IQR, interquartile range; LDL, low‐density lipoprotein; PCSK‐9, proprotein convertase subtilisin/kexin type 9.

High potency is rosuvastatin ≥20 mg, atorvastatin ≥40 mg.

Maximum indicates highest value for a patient for the cholesterol type.

Average indicates (max+min)/2 for a patient for the cholesterol type.

Delta indicates difference between maximum and minimum values for a patient for the cholesterol type.

###### 

Univariate Comparison of Comorbidities Between FH and Non‐FH Cohort

                                                FH Cohort   Non‐FH Cohort   *P* Value           
  --------------------------------------------- ----------- --------------- ----------- ------- ----------
  Total                                         32 613      13.71           205 290     86.29   
  Hypertension                                  21 318      65.37           133 137     64.85   0.07
  Renal disease                                 5659        17.35           30 958      15.08   \<0.0001
  Cancer                                        5938        18.21           37 488      18.26   0.82
  Angina                                        2446        7.50            7354        3.58    \<0.0001
  Myocardial infarction                         4817        14.77           17 092      8.33    \<0.0001
  Heart failure                                 3854        11.82           21 557      10.50   \<0.0001
  MACE[a](#jah34215-note-0008){ref-type="fn"}   9202        28.22           40 832      19.89   \<0.0001
  Ischemic stroke                               2118        6.49            13 044      6.35    0.33
  Ventricular arrhythmias                       1701        5.22            9710        4.73    0.0001
  Percutaneous coronary intervention            3086        9.46            8150        3.97    \<0.0001
  Coronary artery bypass grafting               2488        7.63            10 427      5.08    \<0.0001
  Implantable cardioverter defibrillator        577         1.77            2857        1.39    \<0.0001

FH indicates familial hypercholesterolemia; MACE, major adverse cardiovascular events.

MACE is a composite of death, myocardial infarction, percutaneous coronary interventions, and coronary artery bypass grafting.

![Multivariate models showing outcomes of MACE, mortality, and cost of care for FH diagnosis in the hyperlipidemia cohort. \*Adjusted for age, sex, smoking, diabetes mellitus, hypertension and LDL (max). EHR indicates electronic health record; FH, familial hypercholesterolemia; IRR, incidence rate ratio; LDL, low‐density lipoprotein; MACE, major adverse cardiovascular events.](JAH3-8-e011822-g002){#jah34215-fig-0002}

Cost Analysis {#jah34215-sec-0017}
-------------

Using a complete case analysis methodology, inflation‐adjusted median annual revenue for the FH cohort was higher for each year from 2005 through 2015 (Table [3](#jah34215-tbl-0003){ref-type="table"}). The total follow‐up time for each patient during the study period for analysis (2005--2015) was used as an offset variable to normalize the total amount to a per‐year basis. The median follow‐up time was 11 years (IQR, 3 years) for the FH cohort and 10 years (IQR, 6 years) for the non‐FH cohort.

###### 

Cost of Care: Comparison of Yearly Revenue for the Years 2005--2015 (US\$)

                                        Adjusted Revenue 2005--2015   *P* Value                     
  ------------------------------------- ----------------------------- ----------- -------- -------- ----------
  2005                                  810                           1914        687      1586     \<0.0001
  2006                                  852                           2048        724      1697     \<0.0001
  2007                                  902                           2186        752      1818     \<0.0001
  2008                                  920                           2210        790      1868     \<0.0001
  2009                                  983                           2461        847      2070     \<0.0001
  2010                                  1043                          2680        874      2184     \<0.0001
  2011                                  1044                          2627        867      2153     \<0.0001
  2012                                  1063                          2989        907      2439     \<0.0001
  2013                                  1166                          3370        974      2737     \<0.0001
  2014                                  1294                          4028        1093     3116     \<0.0001
  2015                                  1307                          3818        1005     2846     \<0.0001
  Total adjusted revenue (2005--2015)   17 071                        43 024      11 178   30 876   \<0.0001
  Med net revenue                                                                                   
    2014                                1026                          2687        860      2152     \<0.0001
    2015                                1089                          2788        850      2123     \<0.0001

FH indicates familial hypercholesterolemia; IQR, interquartile range.

In the negative binomial regression model, by including the total follow‐up time (defined as the years between first and last encounter over 2005--2015) as the offset variable to normalize the total adjusted revenue to a per‐year basis, the incidence rate ratio for the total revenue per year in the FH cohort was 1.30 (95% CI, 1.28--1.33; *P*\<0.0001), after adjusting for age, sex, smoking, diabetes mellitus, hypertension, and maximum LDL‐C. There were no significant differences in baseline characteristics of patients with missing financial data compared with those for whom data were available.

Medicare rate‐adjusted median revenue for the FH cohort was 19% higher than the non‐FH cohort for the year 2014 (\$1026 versus \$860; *P*\<0.0001) and 28% higher in 2015 (\$1089 versus \$850; *P*\<0.0001). These trends were maintained when the analysis was repeated with exclusion of possible FH (Tables [S8 and S9](#jah34215-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah34215-sec-0018}
==========

Our study is one of few based on integrated health system data with population coverage of \>3 million residents, including several areas designated as rural, with longitudinal follow‐up of \>10 years. Using the modified DLCN criteria, an EHR‐based algorithm in our population was able to identify an FH cohort within an already high‐risk diagnosis of hyperlipidemia. Use of the modified DLCN criteria in this population‐based manner is methodology not unique to our study.[10](#jah34215-bib-0010){ref-type="ref"}, [11](#jah34215-bib-0011){ref-type="ref"} The designation of FH in the overall hyperlipidemia group had a prevalence of 13.7% and 2.7% of our entire EHR cohort. The prevalence of FH is variable[4](#jah34215-bib-0004){ref-type="ref"}, [10](#jah34215-bib-0010){ref-type="ref"}, [12](#jah34215-bib-0012){ref-type="ref"}, [13](#jah34215-bib-0013){ref-type="ref"} depending on the population studied and case definitions used, ranging from 1:137 (0.7%)[10](#jah34215-bib-0010){ref-type="ref"} to 1:250 (0.4%).[3](#jah34215-bib-0003){ref-type="ref"} The SEARCH (Screening Employees and Residents in the Community for Hypercholesterolemia) study by Safarova et al[11](#jah34215-bib-0011){ref-type="ref"} was based on 131 000 individuals seen in primary care practice and used a unique phenotyping algorithm using structured data and natural language processing for family history and presence of FH stigmata on physical examination for identification of FH in EHR and identified a prevalence of FH of 0.32%. This study comes the closest in methodology to our examination, but there are important differences. First, we used data from the entire spectrum of healthcare delivery systems, including outpatient as well as inpatient data, irrespective of the type of practice. Another notable distinction is our inclusion of "possible FH" in the FH cohort definition. Although this may lead to a degree of misclassification bias for FH (as evidenced by a total prevalence of 2.7% in the entire cohort), our approach was to be inclusive, as this strategy helped identify higher‐risk individuals within the larger EHR cohort. We felt that this was prudent, as the ability of EHR data alone to accurately differentiate between possible and probable FH may be limited. Furthermore, we believe that being inclusive better suits the objective to preemptively screen patients to identify those likely to be at higher risk who would be candidates for more intensive clinical phenotyping to confirm FH status. A combination of only definite and probable FH groups in our study would yield a prevalence of 0.19% in our entire EHR population and 0.98% in the hyperlipidemia cohort. We report a higher proportion of female subjects in our FH cohort as has been reported previously in a meta‐analysis of 6 large population‐based studies that included 37 889 patients.[14](#jah34215-bib-0014){ref-type="ref"}

The EHR‐based FH designation in our study was associated with higher cholesterol levels and traditional comorbidities and correlated with MACE and all‐cause mortality. Benn et al[10](#jah34215-bib-0010){ref-type="ref"} examined the prevalence of FH and the risk of cardiovascular disease in a population of 69 016 individuals from the Danish general population and reported an odds ratio of 13.2 (95% CI, 10.0--17.4) for coronary artery disease for patients with FH not receiving lipid‐modifying therapies and 10.3 (95% CI, 7.8--13.8) for patients with FH receiving lipid‐modifying therapies, compared with patients without FH and not receiving lipid‐modifying therapies. Perak et al[15](#jah34215-bib-0015){ref-type="ref"} reported that the FH phenotype was associated with substantially elevated 30‐year coronary heart disease risk, with hazard ratios up to 5.0 (95% CI, 1.1--21.7). Similar patterns of results were found for total atherosclerotic cardiovascular disease risk, with hazard ratios up to 4.1 (95% CI, 1.2--13.4). The variable phenotypic expression of heterozygous FH is modulated in part by the underlying traditional cardiovascular risk factors,[16](#jah34215-bib-0016){ref-type="ref"} including obesity, diabetes mellitus, smoking, hypertension, male sex, and age, in addition to the risk associated with increased LDL‐C. Using an *ICD*‐based approach, we identified clinical outcomes that would represent the typical burden of atherosclerotic vascular disorder and combined them to define MACE for our study. To assess the utility of our EHR‐based FH assignment in correlating to outcomes, we decided a priori to adjust for traditional risk factors, namely, age, sex, smoking status, diabetes mellitus, hypertension, and maximum LDL‐C in our multivariate model. We observed odds ratios of 4.02 and 1.20 for MACE and mortality, respectively. These slightly lower odds ratios with regard to the studies cited above are expected, as our cohort is not derived from an FH disease‐specific database. More importantly, our comparison population also has hyperlipidemia, which constitutes a difference in methodology from the quoted studies and would lower the reported odds ratios.

Our purpose with this investigation was to show the viability of a large population‐based methodology to identify diverse FH phenotypes within an already high‐risk group of hyperlipidemias and show that such a methodology has consistency in identifying phenotypes associated with adverse outcomes and increased costs of care. We report on differences in death, ischemic heart disease, congestive heart failure, and implantable cardiac defibrillator use. While worse cardiac outcomes such as myocardial infarction have been reported in FH patients previously,[17](#jah34215-bib-0017){ref-type="ref"} the data on ischemic stroke have been variable.[18](#jah34215-bib-0018){ref-type="ref"} This more expansive assessment of comorbidities allowed us to attempt to explain the higher costs of care.

Only 79% of our EHR FH cohort was on statin treatment and only 42% on high‐potency statins. Undertreatment of FH as seen in our analysis has been widely reported previously.[4](#jah34215-bib-0004){ref-type="ref"}, [19](#jah34215-bib-0019){ref-type="ref"}, [20](#jah34215-bib-0020){ref-type="ref"}, [21](#jah34215-bib-0021){ref-type="ref"} These data again underline the role preemptive identification can play in early and adequate treatment of these individuals.

In our study, using revenue data, we determined that the FH designation was associated with consistently higher median costs of care across 12 years of longitudinal data. FH individuals can incur significant costs to the healthcare system over their lifetime attributable to premature atherosclerosis, and more so if not identified and treated.[4](#jah34215-bib-0004){ref-type="ref"} Prior studies exploring the economics of FH have been evaluations of screening strategies[22](#jah34215-bib-0022){ref-type="ref"} or therapeutic interventions,[23](#jah34215-bib-0023){ref-type="ref"} but less is known about the overall economic burden associated with FH. This is a needed area of research to support FH‐related economic evaluations. Our study provides evidence of higher total median costs (reflected in revenue) for FH patients almost twice that of their non‐FH hyperlipidemia counterparts. This differential is maintained across time and appears to be expanding. Using an inverse probability of treatment weights multivariable model, the EHR FH flag was associated with higher median total revenue per year (incidence rate ratio, 1.30; *P*\<0.0001). These results add to current knowledge about higher morbidity and associated cost of care for this high‐risk population and can be helpful in studying the cost effectiveness of novel therapies. We believe that our approach is a novel way of assessing the hidden economic impact of FH in a hospital cohort and can be extrapolated to other health systems.

Cost‐effectiveness analyses of a targeted genetic (cascade) screening program for relatives of patients with FH have been extensively published previously.[24](#jah34215-bib-0024){ref-type="ref"}, [25](#jah34215-bib-0025){ref-type="ref"} However, the yield of an EHR‐based phenotyping algorithm to identify FH within the larger hyperlipidemia cohort as performed in our study is less common and could represent an important missed opportunity to use already available clinical data, which could then be advanced to the next level of targeted screening in the most cost‐effective manner. This potentially promising approach of using EHR‐based phenotyping to identify FH patients and then screen family members to efficiently achieve targeted population‐based FH screening is in need of additional evidence of effectiveness and costs for economic evaluation. Our approach is similar to that of the FH Foundation that recently launched the Find FH program, a machine‐learning algorithm used to identify individuals with probable FH using EHR data, laboratory results, and claims databases.[26](#jah34215-bib-0026){ref-type="ref"}

Limitations {#jah34215-sec-0019}
-----------

This is a retrospective observational study based on a population‐based cohort in a single healthcare system that is geographically limited and ethnically homogenous. Therefore, generalizability of our results to other, more diverse populations may be limited. However, generalizability of our methodology and approach to identify these high‐risk subjects is possible and desirable. Secondary to the retrospective nature of our study that used a preexisting general EHR, our FH phenotyping was likely affected by incomplete information regarding FH‐specific physical examination findings (in particular tendon xanthomas and arcus) and family history. These missing data may lead to an underestimate of the true prevalence of probable and definite FH in our population. Similarly, the use of EHR data to determine outcomes has its limitations regarding the potential for missing data, but manual review of the records validated that this approach was effective in our system. GHS may represent an ideal case in this regard given the high number of patients receiving most or all of their care at GHS. Finally, estimating the absolute increase in cardiovascular risk resulting from FH is complicated, as case ascertainment using healthcare system--based EHR data is likely to be biased toward patients experiencing symptoms and cardiovascular events.[27](#jah34215-bib-0027){ref-type="ref"} Nonetheless, this is the nature of the big‐data approach and is likely balanced by the real‐life pragmatic information being gathered by this methodology. Cost data were available for medical care utilization only within the GHS, and omitted medical care from other providers; however, it is unknown whether and the extent to which these additional services would change the relative cost outcomes.

Conclusion {#jah34215-sec-0020}
==========

Our study demonstrates a novel and pragmatic approach relying on standardized clinical criteria for identification of FH in a previously available EHR database. We were able to demonstrate the clinical significance of this approach by showing a statistically significant association between patients identified as having FH and adverse cardiovascular outcomes and higher costs of care, compared with those with hyperlipidemia not meeting the criteria for FH. The ever‐increasing use of EHR systems may broaden the appeal for such a population‐based approach to identify high‐risk patient groups, initiate guideline‐based interventions, and improve clinical outcomes.
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